NCT06897202已完成2 期
A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight, and Type 2 Diabetes Mellitus (VESPER-2)
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 133
- 试验地点
- 29
- 主要终点
- Percent change from baseline in body weight at Week 28 (Day 197)
研究概览
简要总结
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
详细描述
This is a 28-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy, safety, and tolerability of four different once-weekly MET097 dosing regimens vs. placebo for body weight loss in adults (18-75 years of age) with obesity or overweight (body mass index [BMI] ≥27 to ≤50 kg/m2) and T2DM . After completing 28 weeks of study treatment, all participants will be followed for approximately 11 weeks after administration of the last dose of study treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •BMI ≥27.0 kg/m2 to ≤50.0 kg/m2 at screening
- •Type 2 diabetes mellitus (*T2DM) for at least 3 months before screening
- •Glycated hemoglobin (HbA1c) value between ≥7.0% (53.0 mmol/mol) and ≤10.5% (91.3 mmol/mol) at Screening and treated with stable therapy for at least 30 days prior to Screening/Visit 1 (diet and exercise alone or in combination with metformin monotherapy and/or SGLT-2)
- •Stable body weight (increase or decrease ≤5 kg) within 3 months prior to screening
排除标准
- •Female who is lactating or who is pregnant
- •Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
- •Fasting triglycerides ≥ 5.6 mmol/L (≥500 mg/dL)
- •Poorly controlled hypertension
- •History of stroke
- •Significant cardiovascular disease including but not limited to unstable angina or valvular heart disease or has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary artery re-vascularization, or congestive heart failure
- •Diagnosis of Type 1 diabetes (history of ketoacidosis, hyperosmolar state/coma, or any other types of diabetes except T2DM)
- •History of acute or chronic pancreatitis
- •Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
- •History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
- •Relevant surgical history including all bariatric or weight loss surgeries
- •SGLT2 inhibitors and/or metformin
- •Had 1 or more episodes of hypoglycemia
研究组 & 干预措施
MET097 Active with titration
Experimental
干预措施: MET097 Injection (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
MET097 Active without titration
Experimental
干预措施: MET097 Injection (Drug)
结局指标
主要结局
Percent change from baseline in body weight at Week 28 (Day 197)
时间窗: Baseline (Week 0) through Week 28 (Day 197)
次要结局
- Change from baseline in fasting serum insulin(Baseline (Week 0) through Week 28 (Day 197))
- Change from baseline in C-peptide(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of HbA1c <7.0% (53.0 mmol/mol)(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of HbA1c ≤6.5% (47.5 mmol/mol)(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of HbA1c <5.7% (38.8 mmol/mol)(Baseline (Week 0) through Week 28 (Day 197))
- Weight reduction (weight loss) from baseline that is ≥ 5%(Baseline (Week 0) through Week 28 (Day 197))
- Weight reduction (weight loss) from baseline that is ≥ 10%(Baseline (Week 0) through Week 28 (Day 197))
- Weight reduction (weight loss) from baseline that is ≥ 15%(Baseline (Week 0) through Week 28 (Day 197))
- Change in glycated hemoglobin A1c (HbA1c)(Baseline (Week 0) through Week 28 (Day 197))
- Change from baseline in fasting plasma glucose (FPG)(Baseline (Week 0) through Week 28 (Day 197))
- Weight reduction (weight loss) from baseline that is ≥ 5%(Baseline (Week 0) through Week 28 (Day 197))
- Weight reduction (weight loss) from baseline that is ≥ 10%(Baseline (Week 0) through Week 28 (Day 197))
- Change from baseline in transthyretin [pre-albumin](Baseline (Week 0) through Week 39 (Day 274))
- Occurrence of hypoglycemia according to American Diabetes Association classifications [ADA 2024](Baseline (Week 0) through Week 39 (Day 274))
- Occurrence of anti-drug antibodies(Baseline (Week 0) through Week 39 (Day 274))
- Change from baseline in serum albumin(Baseline (Week 0) through Week 39 (Day 274))
- Weight reduction (weight loss) from baseline that is ≥ 15%(Baseline (Week 0) through Week 28 (Day 197))
- Change in glycated hemoglobin A1c (HbA1c)(Baseline (Week 0) through Week 28 (Day 197))
- Change from baseline in fasting plasma glucose (FPG)(Baseline (Week 0) through Week 28 (Day 197))
- Change from baseline in fasting serum insulin(Baseline (Week 0) through Week 28 (Day 197))
- Change from baseline in C-peptide(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of HbA1c <7.0% (53.0 mmol/mol)(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of HbA1c ≤6.5% (47.5 mmol/mol)(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of HbA1c <5.7% (38.8 mmol/mol)(Baseline (Week 0) through Week 28 (Day 197))
- Occurrence of treatment-emergent adverse events (TEAEs)(Baseline (Week 0) through Week 39 (Day 274))
- Change from baseline in high-sensitivity C-reactive Protein [hsCRP](Baseline (Week 0) through Week 39 (Day 274))
- Characterize the minimum observed concentration (Cmin)(Baseline (Week 0) through Week 39 (Day 274))
- Characterize the maximum observed concentration (Cmax)(Baseline (Week 0) through Week 39 (Day 274))
- Characterize the area under the concentration versus time curve (AUC)(Baseline (Week 0) through Week 39 (Day 274))
- Characterize the time to maximum concentration (Tmax)(Baseline (Week 0) through Week 39 (Day 274))
研究者
研究点 (29)
Loading locations...
相似试验
已完成
2 期
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult WomenOveractive BladderNCT03475706Velicept Therapeutics, Inc.438
已完成
2 期
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)Overactive BladderNCT03594058Velicept Therapeutics, Inc.1,413
已完成
2 期
Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like IllnessInfluenzaInfluenza -Like IllnessNCT04610047Emergo Therapeutics, Inc.315
已完成
2 期
Norketotifen for the Treatment of Uncomplicated Influenza-like IllnessInfluenza -Like IllnessNCT04043923Emergo Therapeutics, Inc.238
尚未招募
2 期
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or OverweightOverweight and ObesityObesityNCT06606483MindRank AI Ltd300